ABVC BIOPHARMA, INC. (American BriVision Holding Corp.) - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, filed on November 17, 2020, covers events occurring on October 23, 2020, and the closing on November 11, 2020. The registrant, American BriVision (Holding) Corporation, reports the entry into material definitive agreements regarding a private placement of securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of Common Stock and Warrants to two non-U.S. investors under Regulation S.
- Aggregate Net Proceeds: $5,000,000.
- Securities Issued: 2,222,224 shares of Common Stock (1,111,112 per investor) and Warrants to purchase an equal number of shares.
- Warrant Terms: Initial exercise price of $6.00 per share; exercisable immediately; expire three years from issuance.
- Forced Exercise Provision: Company may require cash exercise if the Common Stock closing price equals or exceeds $9.00 for 20 trading days within a 30-day period.
- Placement Agent Fees: $175,000 cash success fee plus 7% of shares sold in the Offering issued as cashless warrants (Comp Warrants) with a $6.00 exercise price.
Material Changes
The filing discloses a material increase in liquidity through the $5,000,000 capital raise. The company amended the Securities Purchase Agreements (SPAs) to permit a rolling closing basis. No prior period financial data is provided in this specific filing for comparison.
Outlook, Risks, and Contingencies
The company has entered into Registration Rights Agreements, obligating it to register the shares issued to investors and the shares underlying the warrants. The transaction is exempt from registration under Regulation S. The filing notes that the description of terms is brief and qualified by reference to the exhibits (SPAs, Amendments, Registration Rights Agreements, and Warrant forms).
Investor Verification Checklist
- Verify the actual receipt of the $5,000,000 net proceeds and the date of fund availability.
- Review the full text of the Registration Rights Agreement (Exhibit 10.3) to understand the timeline and conditions for registering the new shares.
- Confirm the dilution impact of the 2,222,224 new shares and the potential future dilution from the 2,222,224 warrant shares plus the 7% Comp Warrants.
- Check subsequent filings for the status of the rolling closing and whether the full offering was completed.